BI05 Successful treatment with upadacitinib for severe atopic dermatitis in a patient with primary immunodeficiency (CARD11)

Mishal Iqbal,Daniel O’Driscoll,Michael R Ardern-Jones

DOI: https://doi.org/10.1093/bjd/ljae090.293

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract A 42-year-old woman with a history of multiple severe allergies, asthma, urticaria, atopic dermatitis and recurrent bacterial and viral infections was diagnosed with CARD11 deficiency (heterozygous missense mutation dominant-negative) through whole-genome sequencing in 2017. Since adolescence, she had been treated with multiple systemic therapies for atopic dermatitis, including systemic corticosteroids, omalizumab, dupilumab and tralokinumab, which were eventually withdrawn due to treatment failure or intolerable adverse effects. On examination she had widespread severe eczema [Eczema Area and Severity Index (EASI) 24, Patient-Oriented Eczema Measure (POEM) 28, Dermatology Life Quality Index (DLQI) 16]. After discussion with immunology colleagues, the patient was offered treatment with upada­citinib 15 mg once daily. At follow-up 8 weeks later, there was a marked improvement in her eczema with complete resolution of itch (EASI 4, POEM 6, DLQI 2). After 5 months, she developed an episode of shingles, which responded to a 7-day course of high-dose oral aciclovir. She was able to restart treatment on alternate-day dosing of upadacitinib 15 mg. Her eczema remains well controlled. The CARD11 gene encodes a scaffold protein required for nuclear factor-κB activation in response to lymphocyte receptor binding. Homozygous null mutations in CARD11 lead to severe combined immune deficiency, while gain-of-function mutations are associated with lymphoproliferative disease. As in our patient, recently described dominant-negative mutations in CARD11 have been shown to be associated with a severe atopic phenotype, multiple allergies and variable predisposition to infection (Ma C, Stinson J, Zhang Y et al. Germline hypomorphic CARD11 mutations in severe atopic disease. Nat Genet 2017; 49: 1192–201). It is postulated that aberrant CARD11-dependent T-cell receptor signalling results in deficiencies in T-cell proliferation and a T helper (Th)2 bias in immune responses. Upadacitinib is an oral small-molecule Janus kinase (JAK) inhibitor that preferentially binds JAK1, inhibiting multiple cytokines associated with Th2 signalling. Given the reported increase in infectious adverse events compared with placebo in clinical trials, the use of JAK inhibitors in patients with inborn errors of immunity must be approached with great caution. However, in our patient with a severe atopic phenotype, recalcitrant to multiple systemic therapies, targeting the JAK1 pathway has provided a dramatic clinical benefit.

dermatology